Anemia is common among patients with CKD and is known to impair their prognosis. In our study population of CKD stage 3 to 5, the prevalence of anemia was 68%, which is compatible with previously published data showing that 50% to 60% of patients with stage 4 CKD are anemic, and the
prevalence of anemia increases to 75% to 92% in patients reaching stage 5 CKD.
Absolute or relative erythropoietin deficiency is involved in the pathophysiology of CKD-associated anemia.
Although treatment with ESAs markedly improved patient-perceived quality of life and reduced the need for blood transfusions,16 the results from the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR), Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin b (CREATE), and TREAT trials all demonstrated an increased risk of CKD progression or cardiovascular events such as stroke, thrombosis, or death at nearly normal hemoglobin concentrations and higher ESA doses in patients with ND-CKD.
2–4 However, the many confounding factors that accompany CKD may have prevented clinicians from discerning the specific role anemia plays in the poor outcomes.
Anemia is common among patients with CKD and is known to impair their prognosis. In our study population of CKD stage 3 to 5, the prevalence of anemia was 68%, which is compatible with previously published data showing that 50% to 60% of patients with stage 4 CKD are anemic, and theprevalence of anemia increases to 75% to 92% in patients reaching stage 5 CKD.Absolute or relative erythropoietin deficiency is involved in the pathophysiology of CKD-associated anemia. Although treatment with ESAs markedly improved patient-perceived quality of life and reduced the need for blood transfusions,16 the results from the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR), Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin b (CREATE), and TREAT trials all demonstrated an increased risk of CKD progression or cardiovascular events such as stroke, thrombosis, or death at nearly normal hemoglobin concentrations and higher ESA doses in patients with ND-CKD.2–4 However, the many confounding factors that accompany CKD may have prevented clinicians from discerning the specific role anemia plays in the poor outcomes.
การแปล กรุณารอสักครู่..